Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2006-03-07
2006-03-07
Chan, Christina (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C530S387300, C530S388100, C530S388220
Reexamination Certificate
active
07008623
ABSTRACT:
The invention relates to antibodies which bind to the CD23 (FCεRII) type II molecule particularly altered antibodies including antibodies which bind to the CD23 (FCεRII) type II molecule characterized by an affinity constant equal to or greater than 1×109Ka Mol−1, the preparation of such antibodies, pharmaceutical compositions which contain such antibodies and their use in therapy particularly in the treatment of autoimmune and inflammatory disorders.
REFERENCES:
patent: 5658570 (1997-08-01), Newman et al.
patent: 6011138 (2000-01-01), Reff et al.
patent: 0788513 B 1 (1996-02-01), None
patent: 93/02108 (1993-02-01), None
patent: 96/12741 (1996-05-01), None
patent: 98/37099 (1998-08-01), None
Abaza et al, J of Protein Chemistry 11(5): 433-444, 1992.
Ngo et al., 1994, The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495.
Kuby et al., 1994, Immunology, second edition, pp. 85-96.
Couzin et al, Science 300: 1862-1865, Jun. 2003.
Van Noort et al, International Review of Cytology 178: 127-206, 1998.
Bodey et al, Anticancer Research 20: 2665-2676, 2000.
Spitler et al, Cancer Biotherapy 10: 1-3, 1995.
Ward et al, Therapeutic Immunology 2: 77-94, 1995.
Mavromatis et al, J Clin Oncology 21(9): 1874-1881, 2003.
Wakai et al, Hybridoma 12(1): 25-43, Feb. 1993.
J. Bonnefoy et al.: “Production and characterization of a monoclonal antibody specific for the human lymphocyte low affinity receptor for IgE: CD23 is a low affinity receptor for IgE.” The Journal of Immunology, vol. 138, No. 9, (May 1987) pp. 2970-2978, Baltimore, MD, USA.
C. Plater-Zyberk et al.: “Marked amelioration of established collagen-induced arthritis by treatment with antibodies to CD23 in vivo.” Nature Medicine, vol. 1, No. 8, (Aug. 1995) pp. 781-785, New York, NY, USA.
L. Flores-Romo et al.: “Inhibition of an in vivo antigen-specific IgE response by antibodies to CD23.” Science, vol. 261, No. 5124, (Aug. 1993) pp. 1038-1041, Washington, DC, USA.
Kleinau et al. “Importance of CD23 for collagen-induced arthritis: Delayed onset and reduced severity in CD23-deficient mice” J. Immunol. 162:4266-4270 (1999).
Bonnefoy Jean-Yves Marcel Paul
Crowe James Scott
Ellis Jonathan Henry
Rapson Nicholas Timothy
Shearin Jean
Chan Christina
Glaxo Wellcome Inc.
Hecht Elizabeth J.
Huynh Phuong
LandOfFree
Antibodies to CD23, derivatives thereof, and their... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies to CD23, derivatives thereof, and their..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies to CD23, derivatives thereof, and their... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3576367